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Two loci identified through large-scale exome chip analysis, SOS2 and 
ACP1, show evidence for altered kidney development and function 
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Abstract 1	  
Previous genome-wide association studies (GWAS) have identified >50 common 2	  
variants associated with kidney function.  We performed a two-stage meta-3	  
analysis of associations between genotypes from the Illumina exome array and 4	  
estimated glomerular filtration rate based on serum creatinine (eGFRcrea) 5	  
among European ancestry participants from the CKDGen Consortium (NStage1: 6	  
111666 and NStage2: 48343).  In single-variant analyses, we identified SNPs at 7 7	  
new loci (PStage1<3.7x10-7) associated with eGFRcrea (PPMJ1, EDEM3, ACP1, 8	  
SPEG, EYA4, CYP1A1 and ATXN2L), which were mostly common and 9	  
annotated as non-synonymous variants.  In gene-based analysis, functional rare 10	  
variants in three genes, including the novel SOS2, were associated with 11	  
eGFRcrea (PSKAT=5.4x10-8).  Experimental follow-up in zebrafish embryos 12	  
revealed kidney development alterations, including glomerular and renal tubule 13	  
changes in the embryonic kidney of acp1- and sos2-knockdowns. These 14	  
developmental abnormalities are coupled with changes in kidney function, 15	  
including altered blood clearance and heightened edema prevalence.  This study 16	  
expands the number of loci associated with kidney function and identifies novel 17	  
genes with potential roles in kidney formation.  18	  
 19	  
 20	  
 21	  
 22	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Introduction  23	  
Chronic kidney disease (CKD) is considered a complex phenotype with a 24	  
genetic predisposition1.  Previous GWAS have successfully identified multiple 25	  
common genetic risk variants associated with the CKD-defining measures of 26	  
estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio 27	  
(UACR).2-5  Together, these variants explain only a small proportion of the 28	  
variation in eGFR and UACR.6  To comprehensively interrogate protein-coding 29	  
regions and assess the effects of rare variants (minor allele frequency 30	  
[MAF]<1%), we carried out a two-stage meta-analysis of the association between 31	  
eGFRcrea and variants genotyped on the Illumina HumanExome chip 32	  
[http://genome.sph.umich.edu/wiki/Exome_Chip_Design] among 111666 33	  
European ancestry (EA) participants from the CKDGen Consortium and 34	  
assessed the role of genes significantly associated with eGFRcrea in kidney 35	  
development using embryonic zebrafish models.  In secondary analyses, we 36	  
examined associations with eGFRcrea stratified by diabetes status, and in a 37	  
smaller subset of EA participants, we also tested estimated glomerular filtration 38	  
rate based on cystatin C (eGFRcys) and UACR.  An additional 9624 participants 39	  
of African ancestry (AA) were also used in an independent exome-chip discovery 40	  
meta-analysis.  41	  
 42	  
Results 43	  
Up to 120357 participants from 27 studies of EA and up to 11386 44	  
participants from 7 studies of AA were included in Stage 1 analyses for 45	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eGFRcrea, eGFRcys, or UACR.  An additional 48343 participants from 12 46	  
studies of EA were included in Stage 2 analysis of eGFRcrea. All participants 47	  
provided informed consent and each of the studies were approved by its 48	  
governing ethics committee or Institutional Review Boards. Sample 49	  
characteristics and genotyping information for each study are summarized in 50	  
Supplementary Tables 1 and 2. 51	  
In Stage 1 single-variant EA analyses, we identified 33 loci associated 52	  
with eGFRcrea (Table 1 and Supplementary Table 3) that met our a priori chip-53	  
wide significance threshold of P<3.7x10-7(0.05/134299 variants).  Of these, 8 had 54	  
not been identified in association with eGFRcrea from previous GWAS analyses; 55	  
6 were missense variants - rs34611728 (PPM1J), rs78444298 (EDEM3), 56	  
rs11553746 (ACP1), rs2307394 (ORC4), rs55760516 (SPEG), and rs9493627 57	  
(EYA4) - and 2 were GWAS tag SNPs included on the exome chip due to prior 58	  
associations in the NHGRI GWAS Catalog for caffeine/coffee intake7, 8 - 59	  
rs2472297 (intergenic, near CYP1A1) and inflammatory bowel disease9 - 60	  
rs8049439 (intronic, ATXN2L); all were common variants (MAF>1%).  A 61	  
Manhattan plot displaying all 33 chip-wide significant loci is shown in Figure. 1.  62	  
Quantile-quantile (QQ) plots indicated no inflation of the overall p-value 63	  
distribution (Supplementary Figure. 1).  Regional association plots show the 64	  
associations of other variants within the 500 Mb region of the index variant of the 65	  
8 newly identified loci in Supplementary Figure. 2. 66	  
In Stage 2 analyses, we followed up the 8 newly identified eGFRcrea loci 67	  
meeting our significance threshold among an additional 48343 EA participants 68	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from 12 studies (sample characteristics and genotyping information are 69	  
summarized in Supplementary Tables 2 and 4).  All loci but ORC4 met criteria for 70	  
replication (a direction of effect consistent with Stage 1 analysis, a P1-sided<0.05 71	  
from Stage 2 analysis, and P<3.7x10-7 from a combined Stage 1 and Stage 2 72	  
analysis, Table 1).  Because diabetes mellitus is a major risk factor for CKD, we 73	  
assessed the genetic associations at these loci in the presence or absence of 74	  
diabetes to obtain additional insights into potential mechanistic pathways.  In 75	  
total, 11040 and 94677 participants were included in the diabetes stratified and 76	  
non-diabetes stratified analyses, respectively. In analyses stratified by diabetes 77	  
status, the beta-coefficients were directionally consistent and of similar 78	  
magnitude between the strata for 6 out of 7 newly identified loci (Supplementary 79	  
Table 5). 80	  
To identify additional novel loci associated with alternative measures of 81	  
kidney function, we tested the association of single variants with eGFRcys 82	  
(N=32861 EA participants) and UACR (N=31164 EA participants).  All observed 83	  
associations achieving the significance threshold (P<3.7x10-7; Supplementary 84	  
Table 8) have been previously reported in association with eGFRcrea, eGFRcys 85	  
or UACR.3, 4, 6  86	  
To further investigate the role of rare variants in kidney function, we 87	  
performed gene-based tests for 9990 autosomal genes that contained at least 2 88	  
non-synonymous or splice-site variants with MAF<1%.  No evidence of inflation 89	  
was observed in QQ plots for gene-based tests (Supplementary Figure. 3).  90	  
Three genes, SOS2, SLC47A1 and LRP2, met the experiment-wide threshold for 91	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gene-based significance (P<2.5x10-6, 0.05/19922 tests [9961 genes x 2 tests], 92	  
Table 2).  The association for SLC47A1, a renal solute transporter, was driven by 93	  
the presence of a single variant, rs111653425, with MAF ~ 1% (Supplementary 94	  
Table 6).  Common variants at SLC47A1 and LRP2 have been previously 95	  
reported in association with eGFRcrea,4, 6 thus implicating both rare and common 96	  
variants at both loci.4, 6 Conversely, the association with SOS2 was novel  97	  
(PSKAT=5.38x10-8; PT1=3.25x10-6).  No genes reached the threshold for chip-wide 98	  
significance in gene-based associations for eGFRcrea stratified by diabetes 99	  
status, eGFRcys, or UACR.   100	  
To identify genes that may play a role during kidney development, we 101	  
used knockdown zebrafish embryos generated by injecting morpholino 102	  
oligonucleotides (MOs) into single-cell stage embryos. Morpholinos are a 103	  
commonly used tool in zebrafish screens because they enable an efficient 104	  
identification of genes that may have a role in developmental processes. The 105	  
morpholinos targeted genes with non-synonymous variants (ppmj1, acp1, eya4, 106	  
speg, and edem3) and the novel gene-based finding, sos2 (Supplemental Figure 107	  
5A).  General defects in the pronephros or embryonic kidney structure (marked 108	  
by expanded pax2a expression) were observed in acp1 ATG MO- and sos2 ATG 109	  
MO-injected embryos compared to controls (Figure. 2, panels A, E and I; 110	  
P<0.0001 for both).  Both acp1 ATG- and sos2 ATG-knock-downs showed 111	  
elongated proximal tubules (increased slc20a1a expression) compared to the 112	  
control group (Figure. 2, panels B, F and J; mean difference in proximal tubule 113	  
length: sos2=81.7 µm; P<0.0001 and acp1= 74.7 µm; P<0.0001, panel M).  The 114	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increase in proximal tubule length was not a consequence of increased embryo 115	  
length, as both sos2 ATG and acp1 ATG-morphants had significantly reduced 116	  
body length relative to controls (Supplementary Figure 5B). Additionally, acp1 117	  
ATG-knockdowns showed shorter distal tubule length (slc12a3 expression), 118	  
which may be a consequence of reduced body length (Figure. 2, panels C, G and 119	  
K; P<0.0001).  No abnormalities were observed for podocytes (wt1a expression) 120	  
for sos2 or acp1 compared to controls (Figure. 2, panels D, H and L; P>0.05).   121	  
Due to the potential off target effects of morpholinos, these developmental 122	  
findings were validated with secondary splice-site morpholinos designed to target 123	  
the sos2 and acp1 pre-mRNA (Supplementary Figure 5A). The sos2 and acp1 124	  
splice morpholino-injected embryos had significantly increased proximal tubule 125	  
length relative to controls (Supplementary Figure 5C-E). Furthermore, the acp1 126	  
splice-site morpholino injected embryos had shortened distal tubules (slc12a3 127	  
expression) consistent with the phenotype induced by the ATG morpholino 128	  
(Suppementary Figure 5F). The reproducibility of the proximal tubule 129	  
developmental defects with ATG and splice-site morpholinos adds confidence to 130	  
the specificity of the morpholino-induced tubule phenotype.  131	  
Follow-up in situ hybridization experiments to determine expression 132	  
patterns of sos2 and acp1 during zebrafish development did not reveal kidney-133	  
specific expression of sos2 or acp1; however, sos2 and acp1 were broadly 134	  
expressed throughout embryogenesis at key stages of kidney development and 135	  
may be acting to control kidney development (Supplementary Figure 6).  In 136	  
humans, both sos2 and acp1 protein are detected in adult renal tubules10. No 137	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significant developmental abnormalities were observed among MO knockdowns 138	  
for the remaining genes (Supplementary Figure 6C).  These findings suggest that 139	  
both SOS2 and ACP1 may influence embryonic renal development, and that 140	  
genetic influences on kidney development may contribute to variation in kidney 141	  
function. 142	  
We next sought to determine whether sos2 and acp1-mediated 143	  
developmental alterations led to abnormalities in kidney function. In zebrafish, 144	  
edema is a common sign of kidney failure 11.  We first performed an edema 145	  
prevalence study and identified incidence rates of pericardial and global edema 146	  
in sos2 and acp1 morphant larva. Both sos2 and acp1 ATG morpholino injected 147	  
embryos had a heightened incidence of pericardial edema beginning at 72 hpf 148	  
(Figure 3A-C). The sos2 morphants developed severe global edema by 120 hpf, 149	  
while the acp1 morphants presented with only pericardial edema (Figure 3A-C). 150	  
Both sos2 and acp1 morphants showed indications of embryonic lethality by 120 151	  
– 144 hpf (Figure 3A-C).  152	  
An additional metric for kidney function is the assessment of glomerular 153	  
filtration and fluid flow by fluorescent dextran clearance 12. Control, sos2, or acp1 154	  
morphant embryos were injected with equal volumes of rhodamine-labeled 70 155	  
kDA MW dextran in the cardiac sinus venosus at 72 hpf. Dextran clearance rate 156	  
was assessed by the quantification of rhodamine fluorescence intensity in a 157	  
standardized area of the cardiac region at 2, 24, and 48 hours post injection (hpi). 158	  
sos2 and acp1 morphant embryos exhibited decreased dextran clearance at both 159	  
24 and 48 hpi relative to controls (Figure 3D-I, M). Furthermore, renal tubules 160	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marked by fluorescent dextran in sos2 and acp1 morphant larva displayed an 161	  
abnormal morphology (Figure 3J-L). Specifically, the proximal convoluted tubules 162	  
were reduced in size and lacked coiling depth.  Failed clearance of 70 kDa MW 163	  
dextran and abnormal tubular structure suggests that morphants may have 164	  
defects in tubular fluid flow and glomerular filtration.  165	  
We also evaluated heart rate in the sos2 and acp1 morphants relative to 166	  
controls because compromised cardiovascular function could contribute to 167	  
defects in dextran clearance. At 96 hours post fertilization (24 hours after dextran 168	  
injection), the sos2 (145.5 ± 3.854 bpm; p = 0.0028) and acp1 (151.2 ± 2.653 169	  
bpm; p < 0.0001) morphants had an elevated mean heart rate relative to controls 170	  
(127.8 ± 3.353 bpm) (Supplementary Figure 2G). While altered kidney 171	  
development, abnormal tubular structure, edema, and decreased dextran 172	  
clearance all support the conclusion that both sos2 and acp1 are regulators of 173	  
kidney development and function, it remains possible that altered hemodynamics 174	  
contribute to the edema and dextran clearance phenotypes observed.  175	  
 In separate single variant analyses among 9624 AA participants, we 176	  
identified 3 loci in association with eGFRcrea at chip-wide significance 177	  
(Supplementary Table 8, P<3.7x10-7).  These variants were rare and the limited 178	  
availability of AA cohorts prevented replication of these findings. The APOL1 G1 179	  
variant, rs73885319, that were known risk factor for kidney function decline and 180	  
end-stage renal disease in African Americans, was included on the exom array. 181	  
However, it is not associated with eGFRcrea in the AA participants here (P=0.70).  182	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To investigate if the newly identified eGFRcrea loci were also associated 183	  
with diabetes mellitus and arterial hypertension, major risk factors for CKD, we 184	  
tested for associations between the 7 validated eGFRcrea loci with blood 185	  
pressure and type 2 diabetes among EA participants in collaborations with the 186	  
CHARGE Blood Pressure13 and CHARGE Glycemia-Type 2 Diabetes14 Working 187	  
Groups.  Consistent with prior observations, the majority of variants were not 188	  
associated with blood pressure traits or diabetes (Supplementary Table 9).  The 189	  
exception was rs2472297 at the CYP1A1 locus, a GWAS tag SNP previously 190	  
associated with coffee/caffeine intake7, 8. This SNP was also associated with 191	  
systolic and diastolic blood pressure (P=7.4x10-7, and 4.6x10-11, respectively).13  192	  
 193	  
Discussion 194	  
Our main findings are four-fold.  First, we identified and validated 7 loci 195	  
associated with eGFRcrea through genotyping on the exome-chip among 196	  
160009 participants of EA in a two-stage study design.  Second, the majority of 197	  
the newly uncovered associations were for common variants with modest effect 198	  
sizes, which argues against the presence of rare protein-coding variants with 199	  
large effect sizes represented on the exome chip.  Third, we identified one novel 200	  
association for SOS2 through gene-based testing.  Fourth, we demonstrated 201	  
altered kidney development and function in zebrafish sos2 and acp1 knockdowns. 202	  
Our study emphasizes the continued success of efforts combining 203	  
population-based genetics and model organisms to identify genes underlying 204	  
kidney function.4, 15  The zebrafish knockdowns provide a systematic model to 205	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examine the consequences of gene perturbations in the embryonic renal system 206	  
of the fish.  Our zebrafish morpholino experiments revealed a potential role for 207	  
sos2 and acp1 in kidney development and function. Mutations in the SOS gene 208	  
family (SOS1 and SOS2) lead to Noonan syndrome, a congenital RASopathy 209	  
(syndromes caused by germline mutations controlling signal transduction 210	  
pathways) that can feature mild kidney dysfunction16 and renal anomalies.17, 18  211	  
The SOS2 protein is expressed in the glomeruli and tubules of kidneys from adult 212	  
humans10.  Together, these findings provide further evidence for a potential role 213	  
for SOS proteins in kidney development and function. There are no prior reports 214	  
of an association between kidney function and ACP1, a gene that encodes for an 215	  
acid phosphatase involved in the immune response and found in erythrocytes.19 216	  
Our observations of kidney abnormalities in sos2- and acp1-knockdowns provide 217	  
genes and target tissues for prioritization in future studies of more extensive 218	  
functional follow-up, diagnostic screening and potentially drug development.   219	  
Although morpholinos are an efficient tool for the rapid evaluation of 220	  
GWAS hits, they have the potential for off-target effects, and morphant 221	  
phenotypes are not always recapitulated in genetic mutant models. In this study, 222	  
we evaluated sos2 and acp1 kidney development phenotypes using two 223	  
independent morpholinos, which we believe adds confidence in the specificity of 224	  
our phenotypes.  Furthermore, we provided evidence that kidney developmental 225	  
changes correlate with edema and reduced dextran clearance from the blood. 226	  
We believe that our morpholino screen has allowed us to clarify promising 227	  
candidates for further study. Simultaneously, we acknowledge that future studies 228	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in genetic mutants will enhance and clarify these findings.  Since genetic 229	  
knockout techniques do not necessarily recapitulate exact features of the 230	  
identified human variants, future experiments are also needed to evaluate the 231	  
impact of specific variants on kidney development and function. 232	  
The majority of identified novel variants were common.  The strongest 233	  
single-variant association with eGFRcrea to date is the common variant 234	  
rs13329952 at the UMOD locus with an effect size of 0.016 ln(ml/min/1.73 m2) 235	  
(MAF=0.19).15  Given our large discovery sample, our study was adequately 236	  
powered (>80%) to detect effect sizes of 0.11 to 0.008 ln(ml/min/1.73 m2) for very 237	  
rare variants to more common variants (0.0005>MAF>0.10) (details of the power 238	  
calculation can be found in Supplementary Methods).  While the selection of non-239	  
synonymous content was expected to enrich for functional variants with large 240	  
effect sizes, a possible reason for the lack of these findings might be the design-241	  
based, limited coverage of rare variants on the exome chip.  The exome chip was 242	  
primarily designed to assess nonsynonymous rare variants that had been 243	  
observed among ~12,000 sequenced participants that were not selected based 244	  
on kidney disease (http://genome.sph.umich.edu/wiki/Exome_Chip_Design), and 245	  
thus, we would not expect kidney disease causing mutations to be well 246	  
represented on the exome chip. While the convenience and low cost of a chip-247	  
based genotyping array focused on exonic variants were influential in facilitating 248	  
a large number of cohorts to participate needed for a well-powered study, the 249	  
limited coverage of the exome impacted the ability of both single-variant and 250	  
gene-based tests to assess all exonic variation in association with kidney 251	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function.  Thus, we cannot rule out bona fide rare variant associations with 252	  
eGFRcrea. Large-scale whole exome or whole genome sequencing will be able 253	  
to adequately address the unresolved issue of the contribution of rare variants to 254	  
the variation of kidney function in the general population.  Due to limited sample 255	  
size in the diabetes stratum compared to the non-diabetes stratum, we did not 256	  
have adequate power to assess unique genetic associations in the diabetes 257	  
stratified analysis.  We did not implement a random effects meta-analysis as an 258	  
alternative screening procedures for novel loci because the between-study 259	  
heterogeneity was small. The analysis module that we used cannot correctly 260	  
account for the different allele dosage between women and men and therefore 261	  
we were unable to implement association analysis for chromosome X variants. 262	  
While our study supports the observation that gene-based analyses aggregating 263	  
rare non-synonymous variants are able to identify new loci in association with 264	  
common complex phenotypes14, 20-22 and can additionally uncover new rare 265	  
missense variants within known loci, the number of loci identified through gene-266	  
based methods remains a small minority of the findings compared to single-267	  
variant results.  Finally, the zebrafish knockdowns helped us to screen novel loci 268	  
that appear to have a role in kidney development or function.  However, 269	  
extrapolation of the relationship between our novel loci among patients with more 270	  
advanced CKD remains to be determined; follow up studies are needed to 271	  
assess the association of these loci with end-stage renal disease and incident 272	  
CKD.    273	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In summary, we identified 8 novel loci (7 common single variants and 1 274	  
gene with multiple rare coding variants) associated with kidney function. 275	  
Functional experiments in zebrafish highlighted potential roles for SOS2 and 276	  
ACP1 in embryonic kidney development.  Future whole exome and whole 277	  
genome sequencing studies will be needed to assess the full spectrum of rare 278	  
genetic variants on kidney function.  279	  
 280	  
Concise Methods 281	  
Study Participants 282	  
 Across all traits analyzed, a total of 120357 participants from 27 studies of 283	  
European ancestry (EA) were included in Stage 1 of this study. An additional 284	  
48343 participants from 12 studies of EA were included in Stage 2.  A total of 285	  
11386 participants from 7 studies of African ancestry (AA) were also included in 286	  
separate analyses.  Study-specific characteristics are summarized in 287	  
Supplementary Table S1, S2 and S4.  All participants provided informed consent 288	  
and each study was approved by its governing ethics committee or Institutional 289	  
Review Board.  290	  
 291	  
Phenotype Definitions 292	  
 Serum creatinine was measured in each study as described in the Study-293	  
Specific Methods section in the Supplemental Material, and calibrated to the 294	  
National Health and Nutrition Examination Study (NHANES) data to account for 295	  
between-laboratory variation.23, 24  eGFR based on serum creatinine (eGFRcrea) 296	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was estimated using the four-variable MDRD Study Equation.25 Cystatin C, an 297	  
alternative biomarker of kidney function, was measured in a sub-set of 298	  
participating studies.  eGFR based on cystatin C (eGFRcys) was estimated as 299	  
76.7x(serum cystatin C).25  All eGFRcrea and eGFRcys values <15 300	  
ml/min/1.73m2 were set to 15, and those >200 ml/min/1.73m2 were set to 200 to 301	  
avoid undue influence from outliers.  UACR was defined as urinary albumin 302	  
(mg/L) / urinary creatinine (mg/dl)]*100. All analyzed traits (eGFRcrea, eGFRcys, 303	  
and UACR) were natural log (ln)-transformed.  Diabetes was defined as fasting 304	  
glucose ≥126 mg/dl, pharmacologic treatment for diabetes, or by self-report. 305	  
Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic 306	  
blood pressure ≥90 mmHg or pharmacologic treatment for hypertension.15  307	  
 308	  
Genotypes 309	  
 Genotyping was conducted in each study using the Illumina Human 310	  
Exome BeadChip [http://genome.sph.umich.edu/wiki/Exome_Chip_Design.].  311	  
This genotyping array containing 247870 markers focuses on exonic variants 312	  
discovered through exome sequencing of ~12000 individuals. Illumina’s 313	  
GenTrain version 2.0 clustering algorithm in GenomeStudio, zCall,26 or a 314	  
combination of both procedures were used to call genotypes.  To improve 315	  
genotype calling of low frequency and rare variants, genotypes from 8 of the 316	  
contributing cohorts (ARIC, AGES, CHS, FHS, RS, Health ABC, FamHS, and 317	  
JHS) were jointly clustered and called via the CHARGE Consortium algorithm.27 318	  
Other participating cohorts were called individually.  Among them, CROATIA-319	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Korcula and GS applied the cluster file from the CHARGE Consortium for 320	  
genotype calling. Details regarding genotyping and quality control within each 321	  
study are summarized in Supplementary Table S2.  322	  
 323	  
Statistical methods for Stage 1 324	  
 By following a centralized analysis plan, each study performed two sets of 325	  
analyses: single-variant analysis and gene-based analysis.  The primary meta-326	  
analyses were focused on the EA population and a secondary set of meta-327	  
analyses were focused on the AA population due to a substantially smaller 328	  
sample size. Where not specified otherwise, R software was used for data 329	  
management, statistical analyses and graphing.28 330	  
 331	  
 Single-variant analysis 332	  
Each study performed association analyses of the following phenotypes 333	  
and models: 1) ln-transformed eGFRcrea, 2) ln-transformed eGFRcys, 3) ln-334	  
transformed UACR and 4) ln-transformed eGFRcrea stratified by diabetes status. 335	  
These association analyses were based on linear regression models adjusting 336	  
for age, sex, study site (if applicable), family structure (if applicable), and the first 337	  
10 principal components to control for population stratification. All analyses were 338	  
performed assuming an additive genetic effect and all analyses were stratified by 339	  
ancestry.  340	  
For single-variant meta-analysis, study-specific results were combined for 341	  
each trait in a fixed-effects model using METAL.29  We restricted single-variant 342	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meta-analyses to 1) autosomal variants; 2) polymorphic variants; 3) variants 343	  
existing in the joint calling effort within the CHARGE consortium;27 and 4) with 344	  
minor allele count (MAC) ≥20 across all cohorts in each ancestry group. 345	  
Bonferroni correction for the number of variants tested within each ancestry was 346	  
used to set the significance threshold for each analysis (chip-wide significance), 347	  
corresponding to P<3.7x10-7 (0.05/134299 variants) for EA analysis and 348	  
P<5.5x10-7 (0.05/91187 variants) for AA analysis. 349	  
 350	  
Gene-based analysis 351	  
Single-variant analysis methods have limited power to detect association 352	  
for rare variants.  Recently developed gene-based methods, where defined 353	  
variants contained in a gene region are collapsed into one unit for analysis, 354	  
provide additional statistical power30 to investigate the role of rare variants on 355	  
kidney function traits.  356	  
 For gene-based meta-analysis, study-specific results were combined 357	  
using the seqMeta package for R.31  The same phenotypes and covariates were 358	  
used as for single-variant testing and analyses were again stratified by ancestry. 359	  
We used two gene-based tests for aggregated analysis of rare SNVs: 1) T1,30 360	  
which is more powerful when all variants within the gene region affect the 361	  
phenotype in the same direction; and 2) the sequence kernel association test 362	  
(SKAT),32 which allows for bidirectional effects and is more powerful when there 363	  
are both protective and deleterious variants within the same gene.  Both gene-364	  
based tests were restricted to variants with MAF<1% and variants likely to exert a 365	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major effect on the gene product (stop gain/loss, nonsynonymous, or splice-site 366	  
variants based on annotation with dbNSFP (v.2.0).33  Genes containing at least 367	  
two variants with a cumulative MAC ≥2020 were included in the analysis. In total, 368	  
we tested 9990 autosomal genes meeting our established thresholds and filters. 369	  
Bonferroni correction for the number of genes and tests performed was used to 370	  
set the significance threshold for the gene-based analysis corresponding to 371	  
P<2.5x10-6 (0.05/19922 tests [9961 genes x 2 tests]) in EA analysis and P<2x10-372	  
6(25378 tests [12689 genes x 2 tests]) in AA analysis.  373	  
 374	  
Statistical methods for Stage 2 375	  
Chip-wide significant results from single-variant meta-analyses were 376	  
brought forward for testing in Stage 2 where each new study followed the same 377	  
methodology as Stage 1.  Details regarding the genotyping and population 378	  
characteristics of each cohort can be found in Supplementary Tables S2 and S4.    379	  
Study-specific results from Stage 2 cohorts were combined using the 380	  
same meta-analysis approach and software as in Stage 1 (fixed-effects model in 381	  
METAL29).  Criteria for validation were: 1) a direction of effect consistent with 382	  
Stage 1 analysis, and 2) a one-sided p-value<0.05 from Stage 2 analysis and 3) 383	  
P<3.7x10-7 from combined Stage 1 and Stage 2 analysis.  384	  
The percentage of phenotypic variance explained by each novel locus was 385	  
estimated as R2=β2var(SNP)/var(ln(eGFRcrea)), where β2 is the estimated effect 386	  
of the SNP on ln(eGFRcrea), and var(SNP)=2*MAFSNP*(1-MAFSNP). 387	  
Var(ln(eGFRcrea)) was estimated in the ARIC study. All loci were assumed to 388	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have independent effects on the phenotype. 389	  
 390	  
Associations with other traits 391	  
 To examine potential associations of the novel eGFR-associated variants 392	  
with other correlated traits and conditions, we performed external look ups for 393	  
systolic and diastolic blood pressure in collaboration with the CHARGE Blood 394	  
Pressure Working Group (N=145872)13 and for type 2 diabetes (T2D) in 395	  
collaboration with the CHARGE Glycemia-T2D Working Group (N=10240 T2D 396	  
cases and 63105 controls)20 among EA participants.  397	  
 398	  
NHGRI GWAS Catalog and PubMed Queries 399	  
For all newly identified and validated variants, we interrogated the NHGRI 400	  
GWAS Catalog [https://www.ebi.ac.uk/gwas/;10/12/15] for the lead SNP at each 401	  
locus and for SNPs in linkage disequilibrium with the lead SNP (within 1 Mbp and 402	  
r2>0.5 from 1000 Genomes Pilot in CEU; 403	  
http://www.broadinstitute.org/mpg/snap/) to assess association with other traits 404	  
(see Supplementary Table S11 for full listing of GWAS Catalog associations).  405	  
Additionally, for each locus we searched PubMed 406	  
[http://www.ncbi.nlm.nih.gov/pubmed;10/12/15] for publications on kidney/renal 407	  
function or chronic kidney disease. 408	  
 409	  
Functional Studies in Zebrafish 410	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 To investigate a potential role of the newly identified genes during kidney 411	  
development, we assessed the functional consequences of gene knockdown in 412	  
zebrafish embryos.  We used antisense morpholino oligonucleotide (MO) 413	  
technology to knock down genes identified based on validated associations for 414	  
nonsynonymous variants and for novel gene-based loci.  Two independent MO 415	  
probes were used for each gene.  Zebrafish were maintained in accordance with 416	  
established IACUC protocols.  417	  
Morpholinos (Gene Tools) were designed against zebrafish target genes. 418	  
Morpholino sequences are as follows: sos2 (5’ 419	  
GCACCGGGAACAACCACACAACTTT 3’), sos2 (exon 2) (5’ 420	  
CCTGCACCTATAAACACAGAATAGA 3’), ppm1j (5’ 421	  
AATTTGTGACATCAGCGGCACGGTA 3’), acp1 ATG (5’ 422	  
TCCGCTGGAAGCCGVVATATTGGTC 3’), acp1 (exon 1) (5’ 423	  
TATAGCATTTCTTACCCAAGCACAC 3’), speg ATG (5’ 424	  
TCTTCTCTTCAGTAACTTTTCTCAT 3’), edem3 (exon 1) (5’ 425	  
AGTCCTCACACAGACACATACCTCA 3’), and eya4 ATG (5’ 426	  
CAGATCCTGTGTATTCTCCATCAGT). Zebrafish embryos were injected with 427	  
various concentrations of MO (sos2 ATG– 150 uM, sos2 (exon 2) – 400 uM, 428	  
ppm1j ATG, acp1 ATG, and acp1 (exon1) – 400uM, edem3 ATG – 300uM, eya4 429	  
ATG – 400 uM, speg ATG – 100uM) at the one-cell stage. We fixed embryos in 430	  
4% PFA at relevant developmental stages for analysis by in situ hybridization 431	  
(http://zfin.org/ZFIN/Methods/ThisseProtocol.html).  Distinct pronephros 432	  
(embryonic kidney) structures were visualized using a series of established 433	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markers: pax2a (global), wt1a (podocyte), slc20a1a (proximal tubule), and 434	  
slc13a3 (distal tubule). acp1 probe was generated from zebrafish cDNA using the 435	  
following primers: 5’ TGGAGAATAGACAGTGCCGC 3’ (forward 1) and 5’ 436	  
TTTTCACGCTGCTTGCCTTC 3’ (reverse 1), and 5’ 437	  
GTGGAGAATAGACAGTGCCG 3’ (forward 2) and 5’ CAGGAAGGCTTTGCATC  438	  
3’ (reverse 2) . sos2 probe was generated from zebrafish cDNA using the 439	  
following primers: 5’ GTGTTCGAGGAAGGAGCACA 3’ (forward) and 5’ 440	  
TGATGTTCCACCCACTGACG 3’ (reverse).  441	  
Abnormal gene expression patterns were identified by direct comparison 442	  
to control embryos that were injected with a standard control MO designed by 443	  
GeneTools (SynGene, Cambridge, UK).  Developmental phenotypes were 444	  
scored by two independent researchers.  Fisher’s exact tests were used to test 445	  
for normal and abnormal embryonic phenotypes for the pax2a, wt1a and slc13a3 446	  
markers and Student-t test was used to test for differences in proximal tubule 447	  
length for the slc20a1a marker; P<0.05 was set as a threshold for statistical 448	  
significance. To evaluate proximal tubule length, the distance between the most 449	  
anterior and the most posterior tip of the right proximal tubule (from standardized 450	  
dorsal-view images) was measured using the imageJ measurement tool. Fisher’s 451	  
Exact test was used to test for differences in edema prevalence; P<0.05 was set 452	  
as a threshold for statistical significance.  453	  
Dextran clearance experiments were performed following previously 454	  
described protocol12. 72 hours after morpholino injection, embryos were 455	  
anesthetized in a 1:20 dilution of 4mg/ml Tricane in embryo water and placed on 456	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a 2% agarose injection mold. An equal volume of tetramethylrhodamine dextran 457	  
(70,000 MW; Invitrogen) was injected into the cardiac sinus venosus of each 458	  
embryo, and individual embryos were sorted into designated wells for timelapse 459	  
imaging. Fluorescent microscopy images were taken at 2 hpi (74 hpf), 24 hpi (96 460	  
hpf), and 48 hpi (120 hpf) for each sorted embryo to assess loading fluorescence 461	  
and the dextran clearance over time. Fluorescence intensity in the cardiac region 462	  
was measured as the mean grayscale value using Image J as previously 463	  
described34. Remaining fluorescence intensity at each time point was normalized 464	  
to the starting intensity per and plotted as a % of the initial fluorescence intensity. 465	  
To evaluate edema, morpholinos were injected into the single-cell stage embryo 466	  
and embryos were examined every 24 hours for evidence of edema. The number 467	  
of affected embryos was recorded as a fraction of total number of injected 468	  
embryos. 469	  
 470	  
Power calculation 471	  
Power for association was evaluated for eGFRcrea assuming a mean of 472	  
4.5 ln(ml/min/1.73 m2) with standard deviation of 0.2 ln(ml/min/1.73 m2), 473	  
estimates from the European ancestry samples in the ARIC study, using 474	  
QUANTO power calculator, version 1.2.4 (http://biostats.usc.edu/Quanto.html) at 475	  
the significance level of 3.7 x 10-7 for a variant with MAF of 0.1, 0.05, 0.03, 0.01, 476	  
0.005, 0.001, or 0.0005.  In Stage 1 with sample size n= 111,666, there was at 477	  
least 80% power to detect effect sizes of 0.008, 0.011, 0.015, 0.026, 0.036, 0.08, 478	  
or 0.11 ln(ml/min/1.73m2), respectively.  For Stage 2, using one-sided tests, there 479	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was 92% power to detect an effect size of 0.018 for a variant with MAF of 0.02 480	  
(minimum MAF among all 8 SNPs tested) based on 48,343 samples in Stage 2 481	  
and correcting for the 8 SNPs tested.  482	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Figure Legends 842	  
 843	  
 844	  
Figure 1. Manhattan plot for single-variant analysis in eGFRcrea among 845	  
111666 European ancestry participants.  Newly identified variants are in dark 846	  
orange. The gene, ORC4, not successfully replicated, are in orange. Known loci 847	  
are in blue. 848	  
 849	  
Figure 2.  sos2 and acp1 knockdowns result in defective kidney 850	  
development.  A-D). Whole mount in situ hybridization in control embryo 851	  
demonstrates normal expression of kidney markers, including pax2a (global 852	  
kidney, A), slc20a1a (proximal tubules, B), and slc12a3 (distal tubules, C) at 48 853	  
hours post fertilization (hpf), and wt1a (podocytes, D) at 24 hpf. E-L) sos2 and 854	  
acp1 ATG morpholino (MO) knockdown embryos develop glomerular gene 855	  
expression defects (E, I, arrowheads) and display elongated proximal tubules (F, 856	  
J). Knockdown of acp1 shortened the distal tubules, while sos2 knockdown left 857	  
distal tubule slc12a3 expression unaffected (G, K). No abnormalities in podocyte 858	  
marker wt1a were observed for sos2 ATG- and acp1 ATG-MOs (H, L).  M) 859	  
Quantitative assessment of proximal tubule length (slc20a1a expression) shows 860	  
that proximal tubules are elongated in sos2 ATG- and acp1 ATG-MO injected 861	  
embryos.  Student's t-test used to calculate p-values (P).  N) Table of observed 862	  
abnormal embryos and total number examined by kidney markers pax2a, wt1a 863	  
and slc12a3 and MO-injected or control status. Fisher's exact test used to 864	  
calculate p-values (P). 865	  
 866	  
Figure 3. sos2 and acp1 knockdowns result in altered kidney function. A) 867	  
sos2 and acp1 morphants develop edema, which is a sign of kidney failure in 868	  
zebrafish. sos2 morphants display severe global edema at 120 hpf, with fluid 869	  
accumulation in the pericardium (black arrow) and intestinal tract (black star). At 870	  
96 hpf, acp1 morphants have severe pericardial edema (black arrow). B-C) 871	  
Incidence of edema and embryonic lethality in acp1 and sos2 morphants with 872	  
Fisher’s Exact test. * indicates p-value <0.05; ** indicates p-value <0.005; *** 873	  
indicates p-value <0.0001. D-I) Embryos were injected with control, sos2, or acp1 874	  
morpholino at the single cell stage and subsequently injected with 70,000 MW 875	  
fluorescent rhodamine dextran at 72 hpf. Dextran fluorescence intensity was 876	  
measured over 48 hours post injection. Dextran-injected embryos show equal 877	  
loading at 2 hpi. Compared to control embryos, sos2 and acp1 MO injected 878	  
embryos have reduced dextran clearance in the cardiovascular region over time. 879	  
J-L) Morphant embryos have altered convoluted tubule morphology at 120 hpi 880	  
(48 hpi) (white arrows). M) Dextran fluorescence intensity over time as 881	  
normalized to starting fluorescence intensity.  882	  
 883	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Table 1.  Novel variants associated with eGFRcrea in European ancestry participants from single-variant analysis in 884	  
Stage 1 meeting chip-wide significance (P<3.7x10-7) and associations in Stage 2 and combined analysis. 885	  
 886	  
      Stage 1
c Stage 2d Combined 
Locusa dbSNPID Chr Positionb Variation  (Substitution) 
EA/ 
Non-EA  
(EAF) 
Beta 
(SE) P I
2 Beta (SE) 
1-sided  
P 
Beta 
(SE) P 
Prop 
Var 
Exp  
(%) 
PPM1J rs34611728 1 113255456 c.639G>T  (L213F) 
A/C  
(0.13) 
-0.0103 
(0.0013) 1.2E-14 13.2 
-0.0059 
(0.0023) 4.7E-03 
-0.0092 
(0.0011) 3.3E-16 0.05 
EDEM3 rs78444298 1 184672098 c.2236C>T  (P746S) 
A/G  
(0.02) 
-0.0183 
(0.0034) 5.2E-08 15.3 
-0.0225 
(0.0055) 
1.8E-05 
 
-0.0195 
(0.0029) 1.5E-11 0.03 
ACP1 rs11553746 2 272203 c.129C>T  (T95l) 
T/C  
(0.35) 
-0.0049 
(0.0009) 2.0E-07 20.7 
-0.0032 
(0.0016) 2.2E-02 
-0.0045 
(0.0008) 1.0E-08 0.02 
ORC4e rs2307394 2 148716428 c.233A>G  (N78S) 
C/T  
(0.32) 
-0.0058 
(0.0010) 6.8E-09 14.3 
-0.0025 
(0.0016) 6.0E-02 
-0.0049 
(0.0009) 8.4E-09 0.03 
SPEG rs55760516 2 220354108 c.8191A>G  (R2731G) 
G/A  
(0.33) 
0.0059 
(0.0009) 4.8E-10 0.5 
0.0054 
(0.0016) 3.7E-04 
0.0058 
(0.0008) 1.7E-13 0.04 
EYA4 rs9493627 6 133789728 c.829G>A  (G223S) 
A/G  
(0.31) 
0.0061 
(0.0010) 2.3E-10 0.0 
0.0049 
(0.0016) 1.4E-03 
0.0058 
(0.0009) 1.4E-11 0.04 
CYP1A1 rs2472297 15 75027880  intergenic T/C  (0.24) 
0.0057 
(0.0010) 7.0E-08 0.0 
0.0059 
(0.0017) 3.2E-04 
0.0058 
(0.0009) 3.0E-11 0.03 
ATXN2L rs8049439 16 28837515 intronic  C/T  (0.40) 
0.0048 
(0.0009) 1.3E-07 7.1 
0.0045 
(0.0016) 1.8E-03 
0.0047 
(0.0008) 1.2E-09 0.03 
a Loci are named according to the closest gene based on the position of the lead SNP for new loci. 887	  
b Position is reported in UCSC Genome Browser build hg19. 888	  
c Sample size for Stage 1 analysis: N=111666. 889	  
d Sample size for Stage 2 analysis: N=48343. 890	  
e This variant reached chip-wide significance (P<3.7x10-7) in the Stage 1 samples but did not meet validation criteria in Stage 2. 891	  
Abbreviations: EA = effect allele, EAF = effect allele frequency, Chr = chromosome, SE = standard error, P= p-value, 892	  
PropVarExp=proportion of variance in ln(eGFRcrea) explained. 893	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Table 2. Genes associated with eGFRcrea in European ancestry participants from gene-based analyses meeting chip-894	  
wide significance thresholds   (P<2.5x10-6). 895	  
 896	  
Genea Chr cMAF N Variantsb 
T1c SKATd 
Beta SE P P 
LRP2 2 0.070 38 0.003 0.002 6.7E-02 3.5E-7e 
SLC47A1f 17 0.033 4 -0.033 0.004 7.8E-15e 3.4E-12e 
SOS2g 14 0.040 8 0.020 0.004 3.3E-06 5.4E-08e 
 897	  
a Gene name.       898	  
b Number of variants used in analysis.       899	  
c The standard burden test collapses the variants with MAF<1% into a single variable and tests the association between this variable 900	  
with a phenotype30.    901	  
d The sequence kernel association test (SKAT) aggregates individual variant score test statistics32.     902	  
  903	  
e Meets chip-wide significant threshold, P<2.5x10-6.       904	  
f Gene-based association results driven by 1 variant.      905	  
g Novel gene. 906	  
     907	  
Abbreviations: Chr = chromosome, cMAF = cumulative minor allele frequency used in analysis, SE = standard error, P= p-value 908	  
      909	  
 910	  
  911	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Figure 1.  912	  
 913	  914	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Figure 2. 915	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Figure 3. 918	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